BridgeBio Oncology Therapeutics, Inc. - Common Stock (NQ:BBOT)

9.350 +0.130 (+1.41%)

Streaming Delayed Price Updated: 4:00 PM EDT, Apr 17, 2026 Add to My Watchlist

Price and Volume

Volume	586,335
Open	9.360
Bid (Size)	9.330 (2,900)
Ask (Size)	9.940 (500)
Prev. Close	9.220
Today's Range	9.235 - 9.648
52wk Range	8.080 - 14.87
Shares Outstanding	N/A
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

April 13, 2026

From TheRas, Inc. (d/b/a BBOT)

Via GlobeNewswire

BBOT Announces Multiple Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2026

March 18, 2026

From TheRas, Inc. (d/b/a BBOT)

Via GlobeNewswire

Performance

YTD	-23.9%	-23.9%
1 Month	+5.3%	+5.3%
3 Month	-18.1%	-18.1%
6 Month	-16.1%	-16.1%
1 Year	-24.8%	-24.8%

More News

This Fund Bought $28 Million of a Beaten-Down Immunotherapy Stock Last Quarter. What Should Long-Term Investors Know? ↗

March 16, 2026

Via The Motley Fool

This $64 Million Biotech Exit Seemingly Missed a 77% One-Day Surge on Gilead Takeover Deal ↗

March 16, 2026

Via The Motley Fool

Biotech Stock Up Nearly 300% Draws $68.7 Million Bet as Breast Cancer Drug Targets 2027 Launch ↗

March 16, 2026

Via The Motley Fool

This Biotech Stock Up 700% Is Still a Top Holding Despite a $9.3 Million Sale Last Quarter ↗

March 16, 2026

Via The Motley Fool

BBOT Announces Publication in Cancer Discovery Highlighting Preclinical Data Demonstrating BBO-11818 is a Potent and Selective panKRAS Inhibitor

March 06, 2026

From TheRas, Inc. (d/b/a BBOT)

Via GlobeNewswire

BBOT Reports Fourth Quarter and Full Year 2025 Financial Results and Update on Corporate Progress

March 05, 2026

From TheRas, Inc. (d/b/a BBOT)

Via GlobeNewswire

BBOT to Participate in Upcoming Investor Healthcare Conferences

February 12, 2026

From TheRas, Inc. (d/b/a BBOT)

Via GlobeNewswire

BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

February 11, 2026

From TheRas, Inc. (d/b/a BBOT)

Via GlobeNewswire

BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

January 13, 2026

From TheRas, Inc. (d/b/a BBOT)

Via GlobeNewswire

BBOT Announces New Clinical Data Advancing Its Portfolio of Three Innovative and Differentiated RAS and PI3Kα Pipeline Programs

January 07, 2026

From TheRas, Inc. (d/b/a BBOT)

Via GlobeNewswire

Is Rapport Therapeutics Stock a Buy After Investment Firm Cormorant Raised Its Stake Over $60 Million? ↗

December 22, 2025

Via The Motley Fool

BBOT to Present at the 44th Annual J.P. Morgan Healthcare Conference

December 16, 2025

From TheRas, Inc. (d/b/a BBOT)

Via GlobeNewswire

BBOT Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

December 11, 2025

From TheRas, Inc. (d/b/a BBOT)

Via GlobeNewswire

BBOT Announces Late-Breaking Preclinical Data on BBO-10203, a First-in-Class RAS:PI3Kα Breaker, at the San Antonio Breast Cancer Symposium (SABCS)

December 10, 2025

From TheRas, Inc. (d/b/a BBOT)

Via GlobeNewswire

BBOT to Participate in Upcoming December Investor Healthcare Conferences

November 18, 2025

From TheRas, Inc. (d/b/a BBOT)

Via GlobeNewswire

BBOT Reports Third Quarter 2025 Financial Results and Update on Corporate Progress

November 12, 2025

From TheRas, Inc. (d/b/a BBOT)

Via GlobeNewswire

BBOT to Participate in the Jefferies Global Healthcare Conference in London

November 03, 2025

From TheRas, Inc. (d/b/a BBOT)

Via GlobeNewswire

BBOT Announces Poster Presentations at the San Antonio Breast Cancer Symposium (SABCS)

October 30, 2025

From TheRas, Inc. (d/b/a BBOT)

Via GlobeNewswire

Preclinical Data Presented at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Support Potential of BBO-10203, a First-in-Class RAS:PI3Kα Breaker That Inhibits KRAS-Mutant Tumor Growth without Inducing

October 25, 2025

From TheRas, Inc. (d/b/a BBOT)

Via GlobeNewswire

BBOT Presents Preclinical Data Demonstrating Potential of BBO-11818 as a Potent panKRAS Inhibitor at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

October 23, 2025

From TheRas, Inc. (d/b/a BBOT)

Via GlobeNewswire

BBOT Announces Poster Presentations at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

October 13, 2025

From TheRas, Inc. (d/b/a BBOT)

Via GlobeNewswire

Frequently Asked Questions

Is BridgeBio Oncology Therapeutics, Inc. - Common Stock publicly traded?

Yes, BridgeBio Oncology Therapeutics, Inc. - Common Stock is publicly traded.

What exchange does BridgeBio Oncology Therapeutics, Inc. - Common Stock trade on?

BridgeBio Oncology Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for BridgeBio Oncology Therapeutics, Inc. - Common Stock?

The ticker symbol for BridgeBio Oncology Therapeutics, Inc. - Common Stock is BBOT on the Nasdaq Stock Market

What is the current price of BridgeBio Oncology Therapeutics, Inc. - Common Stock?

The current price of BridgeBio Oncology Therapeutics, Inc. - Common Stock is 9.350

When was BridgeBio Oncology Therapeutics, Inc. - Common Stock last traded?

The last trade of BridgeBio Oncology Therapeutics, Inc. - Common Stock was at 04/17/26 04:00 PM ET

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.